DelveInsight’s, “Tuberculosis Pipeline Insight, 2021,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Tuberculosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Some of the Tuberculosis Companies are:
- Qurient Co
- Kadmon Gene Therapy Holdings
- Catabasis Pharmaceuticals
- Sequella
- Archivel Farma
- AJ Vaccines
- Sanofi Pasteur
- Aeras
- Immune Network
- Crucell
- Silence Therapeutics
- Biofabri
- GlaxoSmithKline
- NEARMEDIC
- Otsuka Pharmaceutical
- LegoChem Biosciences
- Spero Therapeutics
- Tianjin CanSino Biotechnology
- AnHui Longcom Biologic Pharmacy
- Shanghai Jiatan Pharmatech
- GC Pharma
- And Many Others
Request for Free Sample Page: https://www.delveinsight.com/sample-request/tuberculosis-pipeline-insight
DelveInsight’s Tuberculosis Report covers around 35+ products under different phases of clinical development like:
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Some of the Tuberculosis Therapies are:
- Telacebec (Q203)
- VPM1002
- CAT 5571
- And Many Others
Request for Free Sample Page: https://www.delveinsight.com/sample-request/tuberculosis-pipeline-insight
Current Tuberculosis Treatment Scenario and Tuberculosis Emerging Therapies:
- How many companies are developing Tuberculosis drugs?
- How many Tuberculosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tuberculosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tuberculosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Tuberculosis and their status?
- What are the key designations that have been granted to the emerging drugs?
Request for Free Sample Page: https://www.delveinsight.com/sample-request/tuberculosis-pipeline-insight
Table of Contents:
Introduction
Executive Summary
Malaria: Overview
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
Malaria– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Malaria Collaboration Deals
Late Stage Products (Phase III)
- Comparative Analysis
R21: GlaxoSmithKline
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
- Comparative Analysis
KAF156: Novartis
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
- Comparative Analysis
NPC-19: Nobelpharma
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
- Comparative Analysis
Research Programme: Malaria: Carna Biosciences
Drug profiles in the detailed report…..
Inactive Products
- Comparative Analysis
Malaria Key Companies
Malaria Key Products
Malaria- Unmet Needs
Malaria- Market Drivers and Barriers
Malaria- Future Perspectives and Conclusion
Malaria Analyst Views
Malaria Key Companies
Appendix
Request for Detailed TOC: https://www.delveinsight.com/sample-request/tuberculosis-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/tuberculosis-pipeline-insight